by Michael Addelman, University of Manchester A new therapy developed at The University of Manchester is better at treating depression than cognitive behavioral therapy—or CBT—seen as the gold standard by psychologists and health providers. The study, published in Frontiers in Psychology, is the first full-scale randomized trial of metacognitive therapy (MCT), developed by Professor Adrian...
By Rich Haridy Over 30 years ago, a molecule with incredible anti-cancer properties was discovered in sea sponges. However, it was so structurally complex scientists have been unable to synthesize it in large enough quantities to be able to test it in humans. Now a team of scientists has finally made a landmark breakthrough, achieving total synthesis of the molecule in...
PHILADELPHIA -A twist on the molecular mechanism of how a new cancer drug works could aid in better identifying the best treatments for patients for an array of cancers. The finding is described in Molecular Cell in a study led by Eric J. Brown, PhD, an associate professor of Cancer Biology in the Perelman School of Medicine...
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson’s Disease (PD). A paper published in Nature Partner Journal: Parkinson’s Disease notes too many early PD patients wait too long before seeking medicalattention, or start taking symptomatic medications before they are required, thereby dramatically shrinking the pool of candidates for clinical trials. Figure 1. Relationship between time of diagnosis,...
Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Ivosidenib, an oral, targeted inhibitor of the IDH1...
July 10, 2018 by Anna Williams, Northwestern University Two drugs that target different mutations showed encouraging results in treating leukemia, according to recent clinical trials published in the New England Journal of Medicine (NEJM) and The Lancet Oncology. Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia Jessica Altman, MD, ’07 GME, associate professor...
People with a slow developing type of blood cancer may be able to safely come off ‘life-long’ daily treatment in the future and remain free from cancer, the latest results from a University of Liverpool clinical trial suggest. Credit: University of Liverpool Chronic myeloid leukaemia (CML) is diagnosed in around 600 people each year in the UK. The outlook...
